Homozygous variants in pyrroline-5-carboxylate reductase 2 (PYCR2) in patients with progressive microcephaly and hypomyelinating leukodystrophy

Linyan Meng, Taraka Donti, Fan Xia, Zhiyv Niu, Aisha Al Shamsi, Jozef Hertecant, Fatma Al-Jasmi, James B. Gibson, Honey Nagakura, Jing Zhang, Weimin He, Christine Eng, Yaping Yang, Sarah H. Elsea

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Pyrroline-5-carboxylate reductase 2, encoded by PYCR2, is one of the three homologous enzymes that catalyze the last step of proline synthesis. Homozygous variants in PYCR2 have been reported in patients from multiple consanguineous families with hypomyelinating leukodystrophy 10 (HLD10) (MIM: 616420). Here, we report five additional patients from three families with homozygous nonsense or missense variants in PYCR2, identified through clinical exome sequencing. All patients presented with postnatally acquired microcephaly, moderate to profound global developmental delay, and failure to thrive. Brain MRI in these patients showed thin corpus callosum, delayed myelination, and generalized white-matter volume loss. Additional phenotypes that were less consistent among patients included seizures or seizure-like movements, spasticity and ataxic gait, recurrent vomiting, cortical blindness, dysmorphic features, joint contractures, and irritability. Exome sequencing identified homozygous variants in PYCR2 in the proband from each family: c.28C>T (p.(Glu10Ter)), c.796C>T (p.(Arg266Ter)), and c.577G>A (p.(Val193Met)). Subsequent targeted analyses demonstrated co-segregation of the disease with the variant in the family. Despite the metabolic role of PYCR2, routine serum metabolic test in these patients were normal. To further understand the disease etiology and functions of PYCR2, small molecule metabolomics profiling was performed in plasma from three severely affected patients. No significant changes were identified in proline biosynthesis pathway or related metabolites. Studying the clinical features and the metabolic profiles of the PYCR2-deficient patients provides a more comprehensive picture for this newly identified disorder and facilitates further research on the gene function and disease etiology.

Original languageEnglish (US)
Pages (from-to)460-470
Number of pages11
JournalAmerican Journal of Medical Genetics, Part A
Volume173
Issue number2
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Pyrroline Carboxylate Reductases
Microcephaly
Exome
Proline
Seizures
Cortical Blindness
Failure to Thrive
Metabolomics
Metabolome
delta-1-pyrroline-5-carboxylate
Corpus Callosum
Contracture
Gait
Vomiting
Joints

Keywords

  • exome sequencing
  • hypomyelinating leukodystrophy
  • proline synthesis
  • PYCR2
  • pyrroline-5-carboxylate reductase 2

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Homozygous variants in pyrroline-5-carboxylate reductase 2 (PYCR2) in patients with progressive microcephaly and hypomyelinating leukodystrophy. / Meng, Linyan; Donti, Taraka; Xia, Fan; Niu, Zhiyv; Al Shamsi, Aisha; Hertecant, Jozef; Al-Jasmi, Fatma; Gibson, James B.; Nagakura, Honey; Zhang, Jing; He, Weimin; Eng, Christine; Yang, Yaping; Elsea, Sarah H.

In: American Journal of Medical Genetics, Part A, Vol. 173, No. 2, 01.02.2017, p. 460-470.

Research output: Contribution to journalArticle

Meng, L, Donti, T, Xia, F, Niu, Z, Al Shamsi, A, Hertecant, J, Al-Jasmi, F, Gibson, JB, Nagakura, H, Zhang, J, He, W, Eng, C, Yang, Y & Elsea, SH 2017, 'Homozygous variants in pyrroline-5-carboxylate reductase 2 (PYCR2) in patients with progressive microcephaly and hypomyelinating leukodystrophy', American Journal of Medical Genetics, Part A, vol. 173, no. 2, pp. 460-470. https://doi.org/10.1002/ajmg.a.38049
Meng, Linyan ; Donti, Taraka ; Xia, Fan ; Niu, Zhiyv ; Al Shamsi, Aisha ; Hertecant, Jozef ; Al-Jasmi, Fatma ; Gibson, James B. ; Nagakura, Honey ; Zhang, Jing ; He, Weimin ; Eng, Christine ; Yang, Yaping ; Elsea, Sarah H. / Homozygous variants in pyrroline-5-carboxylate reductase 2 (PYCR2) in patients with progressive microcephaly and hypomyelinating leukodystrophy. In: American Journal of Medical Genetics, Part A. 2017 ; Vol. 173, No. 2. pp. 460-470.
@article{09ec21cd1e3648738da7f000e309d829,
title = "Homozygous variants in pyrroline-5-carboxylate reductase 2 (PYCR2) in patients with progressive microcephaly and hypomyelinating leukodystrophy",
abstract = "Pyrroline-5-carboxylate reductase 2, encoded by PYCR2, is one of the three homologous enzymes that catalyze the last step of proline synthesis. Homozygous variants in PYCR2 have been reported in patients from multiple consanguineous families with hypomyelinating leukodystrophy 10 (HLD10) (MIM: 616420). Here, we report five additional patients from three families with homozygous nonsense or missense variants in PYCR2, identified through clinical exome sequencing. All patients presented with postnatally acquired microcephaly, moderate to profound global developmental delay, and failure to thrive. Brain MRI in these patients showed thin corpus callosum, delayed myelination, and generalized white-matter volume loss. Additional phenotypes that were less consistent among patients included seizures or seizure-like movements, spasticity and ataxic gait, recurrent vomiting, cortical blindness, dysmorphic features, joint contractures, and irritability. Exome sequencing identified homozygous variants in PYCR2 in the proband from each family: c.28C>T (p.(Glu10Ter)), c.796C>T (p.(Arg266Ter)), and c.577G>A (p.(Val193Met)). Subsequent targeted analyses demonstrated co-segregation of the disease with the variant in the family. Despite the metabolic role of PYCR2, routine serum metabolic test in these patients were normal. To further understand the disease etiology and functions of PYCR2, small molecule metabolomics profiling was performed in plasma from three severely affected patients. No significant changes were identified in proline biosynthesis pathway or related metabolites. Studying the clinical features and the metabolic profiles of the PYCR2-deficient patients provides a more comprehensive picture for this newly identified disorder and facilitates further research on the gene function and disease etiology.",
keywords = "exome sequencing, hypomyelinating leukodystrophy, proline synthesis, PYCR2, pyrroline-5-carboxylate reductase 2",
author = "Linyan Meng and Taraka Donti and Fan Xia and Zhiyv Niu and {Al Shamsi}, Aisha and Jozef Hertecant and Fatma Al-Jasmi and Gibson, {James B.} and Honey Nagakura and Jing Zhang and Weimin He and Christine Eng and Yaping Yang and Elsea, {Sarah H.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1002/ajmg.a.38049",
language = "English (US)",
volume = "173",
pages = "460--470",
journal = "American Journal of Medical Genetics, Part A",
issn = "0148-7299",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Homozygous variants in pyrroline-5-carboxylate reductase 2 (PYCR2) in patients with progressive microcephaly and hypomyelinating leukodystrophy

AU - Meng, Linyan

AU - Donti, Taraka

AU - Xia, Fan

AU - Niu, Zhiyv

AU - Al Shamsi, Aisha

AU - Hertecant, Jozef

AU - Al-Jasmi, Fatma

AU - Gibson, James B.

AU - Nagakura, Honey

AU - Zhang, Jing

AU - He, Weimin

AU - Eng, Christine

AU - Yang, Yaping

AU - Elsea, Sarah H.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Pyrroline-5-carboxylate reductase 2, encoded by PYCR2, is one of the three homologous enzymes that catalyze the last step of proline synthesis. Homozygous variants in PYCR2 have been reported in patients from multiple consanguineous families with hypomyelinating leukodystrophy 10 (HLD10) (MIM: 616420). Here, we report five additional patients from three families with homozygous nonsense or missense variants in PYCR2, identified through clinical exome sequencing. All patients presented with postnatally acquired microcephaly, moderate to profound global developmental delay, and failure to thrive. Brain MRI in these patients showed thin corpus callosum, delayed myelination, and generalized white-matter volume loss. Additional phenotypes that were less consistent among patients included seizures or seizure-like movements, spasticity and ataxic gait, recurrent vomiting, cortical blindness, dysmorphic features, joint contractures, and irritability. Exome sequencing identified homozygous variants in PYCR2 in the proband from each family: c.28C>T (p.(Glu10Ter)), c.796C>T (p.(Arg266Ter)), and c.577G>A (p.(Val193Met)). Subsequent targeted analyses demonstrated co-segregation of the disease with the variant in the family. Despite the metabolic role of PYCR2, routine serum metabolic test in these patients were normal. To further understand the disease etiology and functions of PYCR2, small molecule metabolomics profiling was performed in plasma from three severely affected patients. No significant changes were identified in proline biosynthesis pathway or related metabolites. Studying the clinical features and the metabolic profiles of the PYCR2-deficient patients provides a more comprehensive picture for this newly identified disorder and facilitates further research on the gene function and disease etiology.

AB - Pyrroline-5-carboxylate reductase 2, encoded by PYCR2, is one of the three homologous enzymes that catalyze the last step of proline synthesis. Homozygous variants in PYCR2 have been reported in patients from multiple consanguineous families with hypomyelinating leukodystrophy 10 (HLD10) (MIM: 616420). Here, we report five additional patients from three families with homozygous nonsense or missense variants in PYCR2, identified through clinical exome sequencing. All patients presented with postnatally acquired microcephaly, moderate to profound global developmental delay, and failure to thrive. Brain MRI in these patients showed thin corpus callosum, delayed myelination, and generalized white-matter volume loss. Additional phenotypes that were less consistent among patients included seizures or seizure-like movements, spasticity and ataxic gait, recurrent vomiting, cortical blindness, dysmorphic features, joint contractures, and irritability. Exome sequencing identified homozygous variants in PYCR2 in the proband from each family: c.28C>T (p.(Glu10Ter)), c.796C>T (p.(Arg266Ter)), and c.577G>A (p.(Val193Met)). Subsequent targeted analyses demonstrated co-segregation of the disease with the variant in the family. Despite the metabolic role of PYCR2, routine serum metabolic test in these patients were normal. To further understand the disease etiology and functions of PYCR2, small molecule metabolomics profiling was performed in plasma from three severely affected patients. No significant changes were identified in proline biosynthesis pathway or related metabolites. Studying the clinical features and the metabolic profiles of the PYCR2-deficient patients provides a more comprehensive picture for this newly identified disorder and facilitates further research on the gene function and disease etiology.

KW - exome sequencing

KW - hypomyelinating leukodystrophy

KW - proline synthesis

KW - PYCR2

KW - pyrroline-5-carboxylate reductase 2

UR - http://www.scopus.com/inward/record.url?scp=85000715818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000715818&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.38049

DO - 10.1002/ajmg.a.38049

M3 - Article

C2 - 27860360

AN - SCOPUS:85000715818

VL - 173

SP - 460

EP - 470

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 0148-7299

IS - 2

ER -